Anxiety or Your Heart? The Question Women Should Not Have to Settle Alone

“It’s probably just anxiety” may be true. It is not a reason to skip the test that would prove it.

Anxiety and cardiac disease produce overlapping symptoms. Both cause chest pain, palpitations, shortness of breath, and a sense of physical threat. The clinical challenge is real. But the sequence in which conclusions are reached matters, and the evidence shows that women are more likely than men to receive anxiety as an explanation before the cardiac evaluation is completed. 4 / Promising The error is not naming anxiety. The error is naming it first.

The Mechanism

Anxiety activates the sympathetic nervous system through the hypothalamic-pituitary-adrenal axis and direct autonomic discharge. The resulting cascade is physiological, not metaphorical. Circulating catecholamines, primarily epinephrine and norepinephrine, increase heart rate, cardiac contractility, and peripheral vascular resistance. They constrict peripheral vessels and dilate central ones. They increase respiratory rate and trigger hyperventilation, which changes blood pH and can produce chest tightness, paresthesias, and lightheadedness through respiratory alkalosis.

Chest wall muscle tension during acute anxiety is real and palpable. Costochondral joints can be tender after sustained tension. Palpitations during a panic attack are not imaginary arrhythmias: they are sinus tachycardia with or without sympathetically triggered premature atrial or ventricular contractions, both of which are genuinely felt and genuinely irregular. The physical reality of anxiety symptoms is not in question.

The overlap with cardiac symptoms is also real. Ischemic chest pain from obstructive coronary artery disease, from microvascular dysfunction, or from coronary vasospasm produces chest pressure, breathlessness, and a sense of dread. Supraventricular tachycardia, an arrhythmia requiring treatment, produces palpitations that are indistinguishable from anxiety-provoked palpitations on history alone. Mitral valve prolapse, hypertrophic cardiomyopathy, and aortic stenosis each produce symptom patterns that overlap with anxiety presentations.

There is no symptom feature that reliably separates anxiety from cardiac chest pain on history alone in most presentations. The point at which symptoms diverge in a clinically meaningful way, such as ischemic ST changes on ECG during symptoms, elevated troponin confirming myocyte injury, or an echocardiogram showing structural pathology, is accessible only through testing. This is not a failure of clinical skill. It is a diagnostic problem that requires diagnostic tools, not a better history.

Coronary vasospasm and microvascular dysfunction add a further complication: both are more prevalent in women, both can be triggered by emotional stress and anxiety states, and both will produce chest pain and ECG changes during symptoms that resolve completely between episodes. A woman with vasospastic angina who is also anxious may have symptoms that are anxiety-triggered coronary spasm, anxiety-driven sympathetic activation, or both simultaneously. These are not competing diagnoses. They are concurrent mechanisms requiring concurrent evaluation.

What the Evidence Shows

Research on sex differences in clinical attribution of chest pain has documented a consistent pattern across multiple settings and decades. 4 / Promising A 2001 study by Schulman and colleagues, published in the New England Journal of Medicine, used standardized patient actors presenting with identical symptoms to physicians and found that race and sex influenced the recommended diagnostic workup. Women were less likely to be referred for cardiac catheterization than men with equivalent symptom profiles.

The VIRGO study (Lichtman et al., JAMA Internal Medicine, 2015), which enrolled 3,501 patients under age 55 who had a confirmed myocardial infarction, documented that young women were significantly more likely than young men to have had their symptoms attributed to non-cardiac causes, including anxiety and stress, before the MI diagnosis was established. This misattribution was not corrected before the infarction was confirmed. Some of these women had been previously told their cardiac symptoms were anxiety-related. The anxiety attribution had not prompted anyone to complete the cardiac workup.

A 2019 systematic review by Mehta and colleagues in the European Heart Journal synthesized sex differences in MI symptom attribution across multiple health systems and found that women presenting with chest pain symptoms consistent with MI were more likely to receive a non-cardiac diagnosis at first presentation, more likely to have their symptoms attributed to psychological causes, and more likely to receive analgesics rather than antiplatelet therapy at initial visit. These differences were not fully explained by age, risk factor burden, or MI type.

The attribution problem is not limited to MI. For palpitations, a 2015 analysis by Sears and colleagues found that women with documented supraventricular tachycardia waited longer to receive electrophysiology referral than men with the same arrhythmia on monitor. The arrhythmia was real and documented. The delay was in clinical response.

For a woman who has already been told her symptoms are anxiety, the chart notation becomes part of the problem. Subsequent treating clinicians read the prior assessment and weight it. New symptoms in a woman with “anxiety” noted in her chart are evaluated in that context. The prior attribution does not just fail to help; it actively impedes the fresh evaluation the new presentation deserves.

Both Can Be Present Simultaneously

The clinical complication that the “anxiety vs. heart” framing obscures is that both conditions can coexist, and frequently do. Women with confirmed cardiac disease have elevated rates of anxiety and depression compared with the general population. The INTERHEART study, which examined risk factors for MI across 52 countries and more than 29,000 participants, found that psychological stress was a significant independent risk factor for MI in both sexes, with effects comparable in magnitude to hypertension. Women with anxiety disorders have elevated rates of certain cardiac conditions including vasospastic angina and palpitation disorders.

The presence of a well-documented anxiety disorder does not reduce the probability of cardiac disease to zero. It coexists alongside it. The clinical error is using the anxiety diagnosis as a filing system: new symptoms go into the anxiety folder without triggering a separate evaluation.

The practical risk is sharpest when symptoms change. A woman whose anxiety typically produces chest tightness during stressful meetings who now develops chest pressure on mild exertion while walking to her car has a symptom with different character, trigger, and clinical implications. Exertional symptoms that resolve with rest are a hallmark of ischemia, not anxiety. The distinction matters, and it will not be caught if all chest pain goes into the same category.

Why Younger Women Face the Greatest Risk from Misattribution

The women most likely to have their cardiac symptoms attributed to anxiety are also the women most likely to have an MI missed: those under 55. Prior probability of MI is lower in younger women than in older women or men of equivalent age. Lower prior probability is a legitimate Bayesian input, but it has been misapplied in clinical practice as a reason to pursue anxiety explanations before completing the cardiac workup rather than as a reason to require more supporting evidence before closing the case.

The VIRGO study data showed that the sex disparity in cardiac attribution was sharpest among the youngest patients in the cohort. Young women with confirmed MI were more likely than young men of the same age to have been previously told their cardiac symptoms were non-cardiac. The prior misattribution did not prevent the MI. It delayed the point at which appropriate cardiac evaluation was started.

Younger women also have higher rates of the MI mechanisms most likely to be missed by standard testing: spontaneous coronary artery dissection, coronary vasospasm, and MINOCA, myocardial infarction with non-obstructive coronary arteries. These mechanisms do not produce the classic atherosclerotic blockage that angiography finds. A younger woman with one of these mechanisms who is labeled as anxious before the workup is complete has not had cardiac disease excluded; she has had obstructive atherosclerosis deprioritized on the basis of her age, which is not the same thing.

What Testing Actually Answers the Question

An ECG recorded during symptoms is the most informative single test for acute cardiac causes. A resting ECG between episodes has substantially lower sensitivity. A woman who has palpitations daily but whose ECG is captured only during a clinic visit without symptoms has an ECG that documents normal sinus rhythm between palpitation episodes, which is not the same as a normal ECG during the episodes in question.

Ambulatory cardiac monitoring is the appropriate test for palpitations. A standard 24-hour Holter captures rhythm over one day. For infrequent symptoms, a 30-day event monitor worn continuously with patient-triggered recording captures the rhythm during actual symptoms. For very infrequent but severe events, an implantable loop recorder records continuously for up to three years. The question “what rhythm is causing my palpitations” has an answer on these monitors. The question is not answerable by history alone.

Troponin testing matters when an episode was severe, prolonged, associated with syncope, or produced symptoms severe enough to prompt emergency evaluation. A single normal troponin at presentation does not rule out NSTEMI; serial measurements over 3 to 6 hours are required. A woman with a history of chest episodes attributed to anxiety who has never had serial troponins drawn during a severe episode has not had MI ruled out for those episodes.

An echocardiogram evaluates structural and functional cardiac anatomy. It finds hypertrophic cardiomyopathy, significant valvular disease, wall motion abnormalities suggesting prior infarction, and diastolic dysfunction not visible to any other non-invasive test. It should be part of any evaluation for unexplained recurrent chest pain or palpitations where cardiac disease has not been excluded.

Microvascular angina and coronary vasospasm may produce normal results across all of these tests between episodes. A clean structural and rhythm workup does not categorically exclude cardiac causes in all women with chest pain. These conditions require specialized testing, including stress cardiac MRI, PET coronary flow reserve measurement, or invasive coronary function testing with acetylcholine and adenosine, and are addressed specifically in the companion articles on microvascular dysfunction and INOCA on this platform.

POTS: The Autonomic Condition Most Often Mistaken for Anxiety in Young Women

Postural orthostatic tachycardia syndrome (POTS) is an autonomic disorder characterized by a sustained heart rate increase of 30 or more beats per minute within 10 minutes of standing, without a drop in blood pressure, accompanied by symptoms of orthostatic intolerance. It affects an estimated 1 to 3 million people in the United States, with approximately 80 percent of those affected being young women. Its symptom profile — palpitations, lightheadedness, chest discomfort, fatigue, and cognitive difficulty — overlaps extensively with both anxiety and cardiac arrhythmia presentations. The Heart Rhythm Society Expert Consensus Statement on POTS from 2015 identified an average time to diagnosis of 4 to 5 years from symptom onset, with the majority of patients receiving psychiatric diagnoses during that interval.

The physiological mechanism involves inadequate cardiovascular compensation when transitioning from supine to standing. In healthy individuals, sympathetic activation and peripheral vasoconstriction compensate for the approximately 500 mL of blood that pools in the lower extremities on standing. In POTS, this compensation fails in different ways depending on the subtype: hyperadrenergic POTS involves excessive sympathetic discharge producing prominent palpitations and anxiety-like states; neuropathic POTS involves denervation of peripheral vasculature; and hypovolemic POTS involves reduced plasma volume with consequent excessive tachycardia as a compensatory response. Each produces the same clinical presentation.

The diagnosis requires an active stand test or tilt table test with continuous heart rate and blood pressure monitoring. The criterion is a sustained heart rate increase of 30 or more beats per minute within 10 minutes of standing, in the absence of orthostatic hypotension. This is not a sophisticated laboratory procedure. It requires standing, measuring, and sustained attention to a criterion that takes ten minutes to confirm. The barrier to diagnosis is that the test is not routinely ordered when a young woman presents with palpitations and fatigue to general medicine.

The attribution to anxiety is sufficiently common and prolonged that anxiety medications, behavioral counseling, and psychiatric referral frequently constitute the majority of care received by women with POTS during the diagnostic interval. The anxiety that develops during this period is often secondary: a rational response to years of disabling symptoms without diagnosis or effective management.

Treatment for POTS is distinct from anxiety management: increased salt and fluid intake to expand plasma volume, compression garments for lower extremity venous pooling, graded cardiovascular exercise training to improve autonomic conditioning, and pharmacological options including beta-blockers to limit the excessive tachycardia, fludrocortisone for volume expansion, and pyridostigmine to enhance peripheral vascular tone. A young woman receiving anxiolytics for POTS-attributed symptoms is receiving treatment for an incorrect diagnosis. The correct diagnosis requires a standing heart rate measurement that has usually never been performed.

What to Do This Week

1. If you have been told your chest pain or palpitations are anxiety and no ECG during symptoms, echocardiogram, or ambulatory cardiac monitoring has been performed, ask specifically which cardiac tests have been done and which have not. Ask for the reports, not just the conclusions.

2. Use precise language when describing symptoms to clinicians: exact location, character (pressure, sharp, squeezing, burning), duration in minutes, associated symptoms (nausea, breathlessness, sweating, faintness), what triggers them and what relieves them, whether they wake you from sleep, and whether anything about them is changing.

3. If you have a known anxiety disorder and develop new or different chest symptoms, name the distinction explicitly: “this feels different from my usual anxiety symptoms” is a clinically meaningful statement. It gives the treating clinician a reason to re-evaluate rather than route the new symptom into the existing diagnosis.

4. Ask specifically whether you have been evaluated for microvascular angina and vasospastic angina. These are cardiac diagnoses, not rare ones, and they require specific testing to find. Standard anxiety versus cardiac evaluations often miss them.

5. If you have been evaluated by emergency medicine but not by a cardiologist, request a cardiology referral. Emergency evaluation appropriately focuses on ruling out immediately life-threatening conditions. It is not designed to complete the full workup for recurrent chest pain syndromes.

The answer to “anxiety or my heart” is sometimes anxiety, sometimes cardiac, and sometimes both running simultaneously. The test determines which. The test is what you are owed before the conclusion is drawn, and the conclusion being comfortable for the clinician to deliver is not the same as the conclusion being supported by the evidence.